NBIX Stock Analysis: Neurocrine Biosciences | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 16.757m USD | 12M Return: 6.4% | US64125C1099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 192M
EPS Trend: 86.6%
Qual. Beats: 3
Rev. Trend: 99.0%
Qual. Beats: 6
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Neurocrine Biosciences is a US-based biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders across the United States and international markets. Headquartered in San Diego, California, and incorporated in 1992, it is classified as a large-cap biotechnology company within the health care sector. As a biotech, its business model is defined by lengthy R&D timelines, high clinical-trial risk, and revenue generation that depends on regulatory approvals, primarily from the FDA.
The companys commercial portfolio includes INGREZZA for tardive dyskinesia and Huntingtons disease chorea, Orilissa for endometriosis, Oriahnn for uterine fibroids, CRENESSITY for congenital adrenal hyperplasia, plus ALKINDI and Efmody. Its clinical pipeline spans movement disorders, major depressive disorder, schizophrenia, bipolar mania, Alzheimers disease, epilepsy, congenital adrenal hyperplasia, and obesity-related metabolic conditions, with candidates including NBI-1117568, NBI-1117567, NBI-921355, and NBI-1070770 in various stages of development.
Neurocrine supplements its internal R&D with license and collaboration agreements with Takeda Pharmaceutical, Sanofi, AbbVie, Xenon Pharmaceuticals, Voyager Therapeutics, Tanabe Pharma, and Nxera Pharma. Such partnerships are a standard biotech mechanism for sharing development risk, funding late-stage trials, and extending geographic or therapeutic reach without bearing full costs internally.
- INGREZZA sales growth drives core revenue and franchise expansion
- Pipeline catalysts in schizophrenia and MDD programs advance
- Competition from Tevas Austedo pressures tardive dyskinesia market share
| Net Income: 702.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 4.57 > 1.0 |
| NWC/Revenue: 27.65% < 20% (prev 56.67%; Δ -29.02% < -1%) |
| CFO/TA 0.19 > 3% & CFO 1.07b > Net Income 702.5m |
| Net Debt (-345.6m) to EBITDA (946.6m): -0.37 < 3 |
| Current Ratio: 2.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.2m) vs 12m ago 2.63% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 74.83% > 50% (prev 62.89%; Δ 11.94% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.18 (Total Current Assets 2.01b - Total Current Liabilities 984.6m) / Total Assets 5.63b |
| B: 0.15 (Retained Earnings 838.4m / Total Assets 5.63b) |
| C: 0.17 (EBIT TTM 863.0m / Avg Total Assets 4.95b) |
| D: 2.22 (Book Value of Equity 3.88b / Total Liabilities 1.75b) |
| Altman-Z'' = 5.18 = AAA |
| DSRI: 0.95 (Receivables 957.3m/728.0m, Revenue 3.70b/2.68b) |
| GMI: 1.01 (GM 98.37% / 97.81%) |
| AQI: 1.52 (AQ_t 0.55 / AQ_t-1 0.36) |
| SGI: 1.38 (Revenue 3.70b / 2.68b) |
| TATA: -0.06 (NI 702.5m - CFO 1.07b) / TA 5.63b) |
| Beneish M = -2.49 (Cap -4..+1) = BBB |
As of November 09, 2026, the stock is trading at USD 164.63 with a total of 1,507,456 shares traded. Over the past week, the price has changed by +12.68%, over one month by +13.14%, over three months by +3.01% and over the past year by +6.35%.
Current recommended Stop Loss: 155.80 (which is 5.4% or 1.7 ATR below the current price).
Neurocrine Biosciences has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy NBIX.
- StrongBuy: 21
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 206.8 | 25.6% |
P/E Trailing = 24.4585
P/E Forward = 14.8148
P/S = 4.9666
P/B = 4.0001
P/EG = 0.2962
Revenue TTM = 3.70b USD
EBIT TTM = 863.0m USD
EBITDA TTM = 946.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 392.3m USD (from shortLongTermDebtTotal, last quarter) (leases 401.8m already included)
Net Debt = -345.6m USD (calculated: Debt 392.3m - CCE 737.9m)
Enterprise Value = 16.4b USD (16.8b + Debt 392.3m - CCE 737.9m)
Interest Coverage Ratio = unknown (Ebit TTM 863.0m / Interest Expense TTM 0.0)
EV/FCF = 15.78x (Enterprise Value 16.4b / FCF TTM 1.04b)
FCF Yield = 6.34% (FCF TTM 1.04b / Enterprise Value 16.4b)
FCF Margin = 28.09% (FCF TTM 1.04b / Revenue TTM 3.70b)
Net Margin = 18.98% (Net Income TTM 702.5m / Revenue TTM 3.70b)
Gross Margin = unknown ((Revenue TTM 3.70b - Cost of Revenue TTM 81.2m) / Revenue TTM)
Tobins Q-Ratio = 2.92 (Enterprise Value 16.4b / Total Assets 5.63b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 392.3m)
Taxrate = 24.63% (229.6m / 932.1m)
NOPAT = 650.4m (EBIT 863.0m * (1 - 24.63%))
Current Ratio = 2.04 (Total Current Assets 2.01b / Total Current Liabilities 984.6m)
Debt / Equity = 0.10 (Debt 392.3m / totalStockholderEquity, last quarter 3.88b)
Debt / EBITDA = -0.37 (Net Debt -345.6m / EBITDA 946.6m)
Debt / FCF = -0.33 (Net Debt -345.6m / FCF TTM 1.04b)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.20% (Net Income 702.5m / Total Assets 5.63b)
RoE = 19.74% (Net Income TTM 702.5m / Total Stockholder Equity 3.56b)
RoCE = 18.59% (EBIT 863.0m / Capital Employed (Total Assets 5.63b - Current Liab 984.6m))
RoIC = 14.59% (NOPAT 650.4m / Invested Capital 4.46b)
WACC = 6.40% (E(16.8b)/V(17.1b) * Re(6.55%) + D(392.3m)/V(17.1b) * Rd(0.0%) * (1-Tc(0.25)))
Discount Rate = 6.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.79 | Cagr: 0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈861.1m ; Y1≈987.1m ; Y5≈1.45b
[DCF] Fair Price = 218.5 (EV 21.9b - Net Debt -345.6m = Equity 22.2b / Shares 101.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 86.65 | EPS CAGR: 23.35% | SUE: 2.61 | # QB: 3
Revenue Correlation: 99.04 | Revenue CAGR: 25.98% | SUE: 3.49 | # QB: 6
EPS current Quarter (2027-03-31): EPS=2.74 | Chg30d=+3.24% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=10.64 | Chg30d=+3.99% | Revisions=+0% | GrowthEPS=+66.5% | GrowthRev=+36.5%
EPS next Year (2027-12-31): EPS=11.97 | Chg30d=+0.81% | Revisions=+0% | GrowthEPS=+12.5% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: -12% (up=2, down=3)